European Cancer Forum 2025: Innovation, Security and Sustainability
DUO-O trial: Durvalumab + Bevacizumab + Olaparib Improves PFS in Newly Diagnosed BRCA-Wild-Type Ovarian Cancer
10 Most Promising Cancer Drugs Not Yet Approved in 2025: Solid Tumors Edition by OncoDaily
Samra Turajlić: Honoured to Receive the 2026 Pezcoller–EACR Translational Cancer Award
Tanja Obradovic: Eventful 2025 Year for Cancer Drugs-45 New or Accelerated Approvals by FDA
A New Invention: Nanoparticle-Based Salivary Biosensor for Early Detection of Oral Squamous Cell Carcinoma
Advancing Childhood Cancer Care at the 2025 St. Jude Global Alliance Convening
CancerWorld Issue #110 (December) is Live
|
Monday
|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
Sunday
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
1 event,
The ESMO Preceptorship on Gastroesophageal Cancer 2026: Bogota is a two-day educational course aimed primarily at oncologists resident in Latin America. It will be held from April 15–16, 2026, in Bogota, Colombia. The application deadline for this preceptorship is February 1, 2026, at 23:59 CET. Successful applicants receive complimentary course registration and accommodation, and a […] |
0 events,
|
0 events,
|
0 events,
|
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|